Abstract
Deceased organ donors in Australia are cared for primarily by intensive care specialists and nurses in close consultation with organ and tissue donor coordinators and transplant teams. There has been a substantial increase in the number of deceased multiorgan donors in Australia over the last 4 years. Most of this increase has resulted from increased utilization of DCD (donation after circulatory death) donors and older DBD (donation after brain death) donors. More than 90% of DBD donors are maintained on vasoactive medication after brain death with noradrenaline being the drug of choice in most ICUs. In contrast, the utilization of hormonal therapies either singly or in combination is highly variable across the country. Use of triiodothyronine (T3) remains controversial. In recent years, T3 has been administered to 24% of DBD donors, usually in combination with methylprednisolone, vasopressin, and insulin as a combined hormonal protocol for potential cardiothoracic organ donors. Management of the DBD donor in Australia would be facilitated by the development of a nationally uniform evidence-based donor management protocol.
On behalf of the Australian Deceased Donor Management Research Group, Members of the Australian Deceased Donor Management Research Group include Anders E.M. Aneman, Deepak Bhonagiri, Tina A. Coco, Amy E. Williams, Geoffrey J. Dobb on behalf of the Australian Deceased Donor Management Research Group, Espedito E. Faraone, Catherine Hannan, Daryl Jones, Peter S. Macdonald, Gerry O’Callaghan, Helen I. Opdam, Francesca M. Rourke, William Silvester, and Jodie Talbot.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ANZICS. The ANZICS statement on death and organ donation. 3rd ed. Brisbane: ANZICS; 2008.
Excell L, Hee K, Russ G. ANZOD Registry Report 2010. Adelaide: Australia and New Zealand Organ Donation Registry; 2010.
Zaroff JG, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28–29, 2001, Crystal City, VA. Circulation. 2002;106:836–41.
ANZOD, Monthly Report on Organ Donation in Australia. 2011.
Hopkinson DN, Bhabra MS, Hooper TL. Pulmonary graft preservation: a worldwide survey of current clinical practice. J Heart Lung Transplant. 1998;17: 525–31.
Oto T, et al. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg. 2006;82:1842–8.
Sundberg R, et al. Improvement of liver preservation quality with UW solution by chlorpromazine pretreatment of the donor in an experimental model. Transplantation. 1989;4:742–4.
TSANZ, Organ transplantation from deceased donors: consensus statement on eligibility criteria and allocation protocols. 2010.
Chang GJ, et al. Expanding the donor pool: can the Spanish model work in the United States? Am J Transplant. 2003;3:1259–63.
Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008;68 Suppl 1:3–10.
Saidi RF, et al. Changing pattern of organ donation at a single center: are potential brain dead donors being lost to donation after cardiac death? Am J Transplant. 2010;10:2536–40.
Oto T, et al. Association between primary graft dysfunction among lung, kidney and heart recipients from the same multiorgan donor. Am J Transplant. 2008;8:2132–9.
Pokorny H, et al. Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients. Clin Transplant. 2005;19:532–6.
Katz K, et al. Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. Resuscitation. 2000;47:33–40.
Nakagawa K, Tang JF. Physiologic response of human brain death and the use of vasopressin for successful organ transplantation. J Clin Anesth. 2011;23:145–8.
Chamorro C, Falcon JA, Michelena JC. Controversial points in organ donor management. Transplant Proc. 2009;41:3473–5.
Rosendale JD, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75:1336–41.
Wheeldon DR, et al. Transforming the “unacceptable” donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant. 1995;14:734–42.
Nath DS, et al. Increased recovery of thoracic organs after hormonal resuscitation therapy. J Heart Lung Transplant. 2010;29:594–6.
Orlowski JP, Spees EK. Improved cardiac transplant survival with thyroxine treatment of hemodynamically unstable donors: 95.2% graft survival at 6 and 30 months. Transplant Proc. 1993;25(1 Pt 2):1535.
Salim A, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001;136:1377–80.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Macdonald, P.S. et al. (2013). Assessment, Monitoring, and Management of Brain-Dead Potential Organ Donors in Australia. In: Novitzky, D., Cooper, D. (eds) The Brain-Dead Organ Donor. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4304-9_19
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4304-9_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4303-2
Online ISBN: 978-1-4614-4304-9
eBook Packages: MedicineMedicine (R0)